Log in to search using one of your social media accounts:

 

Researchers reveal developmental mechanisms behind rare bone marrow disorder

(Charit é - Universit ä tsmedizin Berlin) Myelodysplastic syndrome is an umbrella term used to describe disorders characterized by the bone marrow's inability to produce normal blood cells. Researchers from Charit é - Universit ä tsmedizin Berlin have found that a mutation in a specific tumor suppressor gene is one possible reason why children with a very rare genetic disorder develop myelodysplastic syndrome. Results from this research have been published in the current edition of the Journal of Clinical Investigation.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news

Related Links:

(In)convenience of adding age and comorbidities to prognostic models in myelodysplastic syndromes, Published online: 22 February 2018; doi:10.1038/s41375-018-0064-6(In)convenience of adding age and comorbidities to prognostic models in myelodysplastic syndromes
Source: Leukemia - Category: Hematology Authors: Source Type: research
Conclusions Multiparametric analyses of new automated parameters are useful for discriminating MDS from non-clonal cytopenia.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
CONCLUSIONS:  Treatment with glasdegib in combination with standard chemotherapy was generally well-tolerated and consistent with prior findings, warranting further evaluation of glasdegib-based combinations in patients with AML or high-risk MDS. PMID: 29463550 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
• Improving IPSS-R before transplant did not translate into better survival outcome.• Blast count pre-transplant was highly predictive of post-transplant outcome.• Survival outcome was affected by cytogenetic at diagnosis and the status of cGVHD.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Publication date: Available online 19 February 2018 Source:The Journal of Molecular Diagnostics Author(s): Andreas Bräuninger, Wolfgang Blau, Kristin Kunze, Ann-Kathrin Desch, Alexander Brobeil, Mehmet Kemal Tur, Benjamin Etschmann, Ulrich Günther, Dieter Körholz, Georg Schliesser, Andreas Käbisch, Michael Kiehl, Mathias Rummel, Stefan Gattenlöhner Myelodysplastic syndromes are hematological neoplasias in which immunohistological examination of bone-marrow trephines is important for a definite diagnosis. Unequivocal distinction from reactive bone-marrow changes is, however, sometimes difficult. As...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
Source: American Journal of Hematology - Category: Hematology Authors: Tags: Commentary Source Type: research
Condition:   Myelodysplastic Syndromes Intervention:   Drug: 50 gm CIVI/24 hours x 5 days every 4 week Sponsors:   New York University School of Medicine;   Perlmutter Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Myelodysplastic Syndromes;   Graft Vs Host Disease;   Fungal Infection Interventions:   Drug: Conditioning treatment " Thiotepa-Treosulfan-Fludarabine " ;   Procedure: PBSC graft;   Drug: GvHD prophylaxis;   Drug: Primary antifungal prophylaxis Sponsor:   Ciceri Fabio Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Myelodysplastic Syndromes Intervention:   Drug: 50 gm CIVI/24 hours x 5 days every 4 week Sponsors:   New York University School of Medicine;   Perlmutter Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Myelodysplastic Syndromes;   Graft Vs Host Disease;   Fungal Infection Interventions:   Drug: Conditioning treatment " Thiotepa-Treosulfan-Fludarabine " ;   Procedure: PBSC graft;   Drug: GvHD prophylaxis;   Drug: Primary antifungal prophylaxis Sponsor:   Ciceri Fabio Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Child Development | Children | Genetics | International Medicine & Public Health | Myelodysplastic Syndrome